Humacyte Coronary Tissue Engineered Vessel not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The CTEV is a tissue-engineered acellular vascular conduit regulated as a biological product by the Food and Drug Administration (FDA). The CTEV has an inner diameter of 3.5 mm and with approximately 20 cm of usable length.”In the company’s words, NCT07730528 on ClinicalTrials.gov
- Tested for
- Coronary Artery Disease
- Main trialPhase 2
- “The goal of this study is to assess safety and efficacy of Humacyte's coronary tissue engineered vessel (CTEV) used as a bypass conduit in patients requiring multi vessel coronary artery bypass grafting (CABG). The main question it aims to answer whether the CTEV is feasible as a conduit in CABG surgery. Each participant will be implanted with a CTEV using standard surgical techniques and followed for up to 36 months for routine assessments, including imaging, physical and clinical examinations, vital signs, laboratory assessments, and safety assessments.”In the company’s words, NCT07730528 on ClinicalTrials.gov
Other drugs for Coronary Artery Disease
- XTR004Sinotau Pharmaceutical Group · Phase 3
- EA-230EBI Anti Sepsis BV · Phase 3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- ZiltivekimabNovo Nordisk · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up1
- Sep 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Sep 2030 | Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026